Smith & Nephew Consults Shareholders on Remuneration Policy

TL;DR

SNN consulted shareholders on exec pay policy, seeking approval.

AI Summary

Smith & Nephew plc announced on August 12, 2024, that it has completed further shareholder consultation regarding its 2024 Directors' Remuneration Policy and Restricted Share Plan. The company is seeking to adopt these policies.

Why It Matters

This filing indicates Smith & Nephew is seeking shareholder approval for its executive compensation structure, which can impact investor confidence and future executive decisions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure regarding shareholder consultation on remuneration policies, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

• SMITH & NEPHEW PLC (company) — Registrant
• Smith+Nephew (company) — Company Name
• August 12, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $5.5 billion — ountries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent

Filing Documents

• a0206a.htm (6-K) — 40KB
• 0001654954-24-010275.txt ( ) — 41KB

Forward-looking Statements

Forward-looking Statements   This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks,

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at ww

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.             Smith & Nephew plc     (Registrant)             Date: August 12, 2024 By: /s/ Helen Barraclough     Helen Barraclough     Company Secretary

View Full Filing

View this 6-K filing on SEC EDGAR